A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial
Real Journeys, Real Outcomes: Personalized Peptide Support in Action In this episode of Real Journeys, Real Outcomes, Shanna Hunter, Towatha M
Coffee consumption and disease correlations
Mental clarity and mood improvement are additional benefits of B12 MIC injections
Introduction Chronic hepatitis B virus (HBV) infection remains a serious public health issue, which is the leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) ( The disorder of T cells mediated cellular immune response favored viral persistence and pathogenesis of hepatitis B ( + and CD8 + T cell responses and the production of HBV-related antibodies determine the outcome of HBV infection